Active substance
Hepatitis a virus
- SFDA 4
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| AVAXIM 80U-0.5ML PEDIATRIC VACCINE | 80 U | Suspension for injection in pre-filled syringe · Intramuscular use | 1 Injection Syringe | SAR 66.25 | Biological · Prescription | SANOFI PASTEUR | Valid |
| HAVRIX | 1440 ELISA unit/ml | Suspension for injection · Intramuscular use | 1 Vial | SAR 90.79 | Biological · Prescription | GLAXO SAUDI ARABIA | Valid |
| HAVRIX 720 EFISA UNITS-.5ML JUNIOR VACCI | Solution for injection · Intramuscular use | 1 Injection Syringe | SAR 73.90 | Biological · Prescription | GLAXO SAUDI ARABIA | Valid | |
| VAQTA VACCINE 50 U VIAL | 50 IU/ml | Suspension for injection in pre-filled syringe · Intramuscular use | 1 Vial | SAR 89.55 | Biological · Prescription | MERCK SHARP & DOHME | Valid |
Indications — CHI Daman Drug Formulary
ADULT IMMUNIZATION; MATERNAL AND CHILD HEALTHCARE- IMMUNIZATION FOR MOTHER AND CHILD; TRAVEL IMMUNIZATION
Combinations containing Hepatitis a virus
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.